The NCCN has added zongertinib to its guidelines for the care of patients with HER2 (ERBB2)-mutated non–small cell lung cancer.

BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in ...

A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities ...

Barriers to CAR T-cell therapy exist for patients with multiple myeloma, even in urban areas, said Mary Steinbach, DNP, APRN, ...

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient ...

Panelists discuss how evolving clinical advances and biomarker-driven therapies have transformed treatment practices and ...

Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for ...

Panelists discuss how practice improvements and patient resources can be implemented to empower both healthcare providers and ...

Panelists discuss how they manage adverse events associated with ALK inhibitors, comparing safety profiles and addressing ...

Panelists discuss how they approach long-term monitoring and follow-up care for ALK+ patients to maintain optimal outcomes on ...